

Cleveland Area Reliant IRB Review Process

The Cleveland Area Reliant IRB Review process includes participation by the Case Western Reserve University (CWRU) Social, Behavioral, and Educational Research (SBER) IRB, the Cleveland Clinic (CC) IRB, MetroHealth Medical Center (MHMC) IRB, and University Hospitals Case Medical Center (UHCMC) IRB. The process relies on executed IRB Authorization Agreements (IAA) between the institutions. These agreements document that all applicable human research subjects protection considerations will be made by one Institutional Review Board (IRB), which will be deemed the IRB of record. The IRBs of the other Cleveland area institutions will accept the approval of the IRB of record through the Reliant Review process. The goal is to eliminate duplication of effort and multiple applications for submission of the same protocol, and to encourage scientific collaboration among the affiliated institutions.

What types of studies are eligible for the Reliant Review Process?

Any type of human research study could be eligible for the Reliant Review process. These include but are not limited to investigator-initiated, federally-funded, foundation-supported, industry-sponsored, and non-funded studies.

The fundamental requirement is that a collaborating investigator must be named at each site where the research will occur. It is important for the Principal Investigator at the lead study site to work with the IRB of record throughout the Reliant Review Process to initiate acceptance of IRB approval at each collaborating site.

This is a Clinical Translational Science Collaborative (CTSC) initiative and was developed through the CTSC IRB Task Force and Regulatory Knowledge and Support Core.

For further information, contact:

Kathleen Lawry, Director Reliant Review, MetroHealth Medical Center:
(216) 778-2077, klawry@metrohealth.org

Kim Volarcik, Executive Director Research Compliance, CWRU:
(216) 368-0134, kav6@case.edu